ZURANCMHealthcare·Biotechnology#214 in industry

Zura Bio Limited

Reports in 11d· 2026-05-07

-15.9% · 90d

$5.41

+0.03 (+0.46%)

News

No News Yet

Press releases and SEC filings for ZURA will appear here as they are published.

Check back later for updates

Key Data

Market Cap$512.8M

Open$5.38

Prev Close$5.38

Day Range$5.32 – $5.56

52W Range$0.98 – $7.44

Volume289,650

P/E (TTM)—

EPS$-1.06

Dividend Yield—

Beta0.24

Price Target$15.50(+186.8%)

Next Earnings2026-05-07(11d)

Analyst Ratings

Strong Buy7 analysts

Buy 7Hold 0Sell 0

About

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Healthcare · Biotechnology

40 employees

zurabio.com